This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. AVTX, IRD, IMRX, AADI, ANEB, FBRX, RNTX, ATHE, RNXT, and PRLDShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Avalo Therapeutics (AVTX), Opus Genetics (IRD), Immuneering (IMRX), Aadi Bioscience (AADI), Anebulo Pharmaceuticals (ANEB), Forte Biosciences (FBRX), Rein Therapeutics (RNTX), Alterity Therapeutics (ATHE), RenovoRx (RNXT), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Avalo Therapeutics Opus Genetics Immuneering Aadi Bioscience Anebulo Pharmaceuticals Forte Biosciences Rein Therapeutics Alterity Therapeutics RenovoRx Prelude Therapeutics Immuron (NASDAQ:IMRN) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership. Does the MarketBeat Community prefer IMRN or AVTX? Immuron received 176 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 67.87% of users gave Immuron an outperform vote while only 48.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformImmuronOutperform Votes18867.87% Underperform Votes8932.13% Avalo TherapeuticsOutperform Votes1248.00% Underperform Votes1352.00% Which has preferable earnings and valuation, IMRN or AVTX? Immuron has higher revenue and earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuron$3.21M3.36-$4.55MN/AN/AAvalo Therapeutics$441K92.07-$31.54MN/AN/A Is IMRN or AVTX more profitable? Immuron's return on equity of 0.00% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmuronN/A N/A N/A Avalo Therapeutics N/A -442.16%122.99% Which has more volatility and risk, IMRN or AVTX? Immuron has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Do analysts prefer IMRN or AVTX? Immuron presently has a consensus target price of $5.00, indicating a potential upside of 171.00%. Avalo Therapeutics has a consensus target price of $33.00, indicating a potential upside of 780.00%. Given Avalo Therapeutics' higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do insiders and institutionals have more ownership in IMRN or AVTX? 0.1% of Immuron shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Comparatively, 3.0% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor IMRN or AVTX? In the previous week, Avalo Therapeutics had 1 more articles in the media than Immuron. MarketBeat recorded 1 mentions for Avalo Therapeutics and 0 mentions for Immuron. Immuron's average media sentiment score of 0.00 equaled Avalo Therapeutics'average media sentiment score. Company Overall Sentiment Immuron Neutral Avalo Therapeutics Neutral SummaryImmuron beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$6.46B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.4126.7619.60Price / Sales3.36258.78395.72117.87Price / CashN/A65.8538.3234.62Price / Book1.266.406.764.50Net Income-$4.55M$143.73M$3.23B$248.32M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron2.0192 of 5 stars$1.85-7.8%$5.00+171.0%-19.8%$11.03M$3.21M0.00N/AAVTXAvalo Therapeutics3.4015 of 5 stars$4.00-1.5%$33.00+725.0%-63.8%$43.31M$441,000.000.0040IRDOpus Genetics1.8385 of 5 stars$0.95+0.3%$7.33+671.9%N/A$43.21M$10.99M-0.8714Analyst UpgradeIMRXImmuneering2.2861 of 5 stars$1.19+4.4%$15.33+1,188.5%-6.5%$42.82M$320,000.00-0.6060AADIAadi Bioscience0.5388 of 5 stars$1.70+3.7%$1.67-2.0%-0.3%$41.99M$25.07M-0.7540Negative NewsGap DownANEBAnebulo Pharmaceuticals2.2922 of 5 stars$1.02-1.9%$8.00+684.3%-47.1%$41.91MN/A-3.644High Trading VolumeFBRXForte Biosciences2.9056 of 5 stars$6.28-1.6%$32.50+417.5%+31,233.3%$41.34MN/A-0.395Positive NewsAnalyst DowngradeGap UpRNTXRein TherapeuticsN/A$1.80+2.3%N/AN/A$39.59MN/A-0.589High Trading VolumeATHEAlterity Therapeutics1.9444 of 5 stars$4.39-8.5%$12.00+173.3%+109.5%$38.93MN/A0.0010Gap DownRNXTRenovoRx2.4487 of 5 stars$1.06flat$7.00+560.4%-12.1%$38.75M$43,000.00-1.866Analyst RevisionGap UpPRLDPrelude Therapeutics2.7245 of 5 stars$0.88+13.0%$4.00+353.2%-78.2%$38.50M$7M-0.50120 Related Companies and Tools Related Companies AVTX Competitors IRD Competitors IMRX Competitors AADI Competitors ANEB Competitors FBRX Competitors RNTX Competitors ATHE Competitors RNXT Competitors PRLD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMRN Stock Free IMRN Stock Alerts